vimarsana.com
Home
Live Updates
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers : vimarsana.com
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers
/PRNewswire/ -- EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which...
Related Keywords
Dallas ,
Texas ,
United States ,
University Of Texas ,
Prnewswire Epicentrx ,
David Sher ,
Stephen Sonis ,
Faculty Of The Dana Farber Cancer Institute ,
University Of Texas Southwestern ,
International Journal Of Radiation Oncology ,
International Journal ,
Radiation Oncology ,
Texas Southwestern ,
Harvard Professor ,
Oral Medicine ,
Distinguished Faculty ,
Dana Farber Cancer Institute ,
Epicentrx ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.